In patients with advanced HER2-mutated lung adenocarcinoma who had received platinum-based chemotherapy, pyrotinib monotherapy showed an ORR of 30.0%, median PFS of 6.9 months and median OS of 14.4 months [22]. The gene discussed is ERBB2; the disease is lung adenocarcinoma.